Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.
NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Atara Biotherapeutics, Inc. ("Atara Biotherapeutics, Inc." or the "Company") (NASDAQ:...
NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities...
SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective,...
Atara Biotherapeutics stock plunges after FDA rejects cancer therapy
